Pfizer (PFE) Free Cash Flow (2009 - 2026)
Pfizer (PFE) posted quarterly Free Cash Flow of $2.2 billion for Q1 2026, up 23.04% year-over-year from $1.8 billion in Q1 2025, and down 51.61% quarter-over-quarter from $4.5 billion in Q4 2025.
Pfizer (PFE) Free Cash Flow (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Free Cash Flow for 18 consecutive years, with $2.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 23.04% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $9.5 billion (up 180.23% YoY), while the FY2025 annual figure was $9.1 billion, down 7.73% from the prior year.
- Free Cash Flow declined to $2.2 billion in Q1 2026 per PFE's latest filing, from $4.5 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $7.4 billion in Q3 2022 and bottomed at -$2.4 billion in Q2 2024.
- Historically, Free Cash Flow has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2026.
- Annual changes were most pronounced in 2023 — Free Cash Flow sank 128.6% — and 2024, when it surged 428.77%.
- Pfizer's Free Cash Flow stood at $7.4 billion in 2022, then sank by 43.44% to $4.2 billion in 2023, then declined by 3.93% to $4.0 billion in 2024, then grew by 11.71% to $4.5 billion in 2025, then tumbled by 51.61% to $2.2 billion in 2026.
- Business Quant data shows PFE's Free Cash Flow at $2.2 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 302.00 Mn |
| Jun 28, 2026 | 302.00 Mn |
| Mar 29, 2026 | 2.18 Bn |
| Mar 29, 2026 | 2.18 Bn |
| Dec 31, 2025 | 4.50 Bn |
| Dec 31, 2025 | 4.50 Bn |
| Sep 28, 2025 | 4.00 Bn |
| Sep 28, 2025 | 4.00 Bn |
| Jun 29, 2025 | -1.20 Bn |
| Jun 29, 2025 | -1.20 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Sep 29, 2024 | 4.03 Bn |
| Sep 29, 2024 | 4.03 Bn |
| Jun 30, 2024 | -2.42 Bn |
| Jun 30, 2024 | -2.42 Bn |
| Mar 31, 2024 | 386.00 Mn |
| Mar 31, 2024 | 386.00 Mn |
| Dec 31, 2023 | 4.20 Bn |
| Dec 31, 2023 | 4.20 Bn |